Nanomerics
Nanomerics is a clinical stage company developing therapeutic pipelines with focus on ophthalmology and CNS conditions. They develop precision medicines using proprietary platform technologies for drug delivery, including their award-winning Molecular Envelope Technology (MET). Their pipeline includes ophthalmic medicines and CNS assets, with ongoing clinical trials and collaborations. The company aims to create better medicines through innovative nanotechnology and drug delivery systems, with a strong emphasis on safety, efficacy, and addressing unmet medical needs.
Industries
Nr. of Employees
small (1-50)
Nanomerics
Nanomerics Ltd., Northwick Park and St Mark’s Hospital, Y Block, Watford Road, Harrow, Middlesex, HA1 3UJ
Patents
Products
Polymeric molecular envelope drug delivery platform (excipient)
A platform of tailored biocompatible polymers that self-assemble into nanoparticles to solubilise and deliver hydrophobic small molecules, peptides and nucleic acids across epithelial barriers.
Ophthalmic eye drop candidates for anterior and posterior eye disease
Topical aqueous eye drop medicine candidates formulated to treat conditions such as allergic conjunctivitis, dry eye disease and retinal conditions using the polymeric delivery platform.
Mucoadhesive antiviral nasal polymer formulation (preclinical)
Polymer-based nasal spray formulations demonstrating antiviral activity in vitro and ex vivo, developed as prophylactic nasal sprays to reduce respiratory virus transmission.
Intranasal powder pain therapeutic formulation (partner‑developed)
An intranasal powder formulation of an analgesic peptide-based therapeutic developed using the delivery platform and progressed under out‑licence to a third-party developer for clinical development.
Polymeric molecular envelope drug delivery platform (excipient)
A platform of tailored biocompatible polymers that self-assemble into nanoparticles to solubilise and deliver hydrophobic small molecules, peptides and nucleic acids across epithelial barriers.
Ophthalmic eye drop candidates for anterior and posterior eye disease
Topical aqueous eye drop medicine candidates formulated to treat conditions such as allergic conjunctivitis, dry eye disease and retinal conditions using the polymeric delivery platform.
Mucoadhesive antiviral nasal polymer formulation (preclinical)
Polymer-based nasal spray formulations demonstrating antiviral activity in vitro and ex vivo, developed as prophylactic nasal sprays to reduce respiratory virus transmission.
Intranasal powder pain therapeutic formulation (partner‑developed)
An intranasal powder formulation of an analgesic peptide-based therapeutic developed using the delivery platform and progressed under out‑licence to a third-party developer for clinical development.
Services
Structuring and managing licensing agreements and collaborative development relationships with third‑party developers and commercial partners.
Coordination of Phase I tolerability studies with contract research organisations to execute first‑in‑human testing under GCP.
Structuring and managing licensing agreements and collaborative development relationships with third‑party developers and commercial partners.
Coordination of Phase I tolerability studies with contract research organisations to execute first‑in‑human testing under GCP.
Expertise Areas
- Ocular drug delivery and topical ophthalmic formulations
- Intranasal nose‑to‑brain delivery
- Polymeric nanotechnology and supramolecular self‑assembly
- Formulation development for hydrophobic small molecules, peptides and nucleic acids
Key Technologies
- Polymeric supramolecular nanoparticle carriers
- Nano‑in‑micro powder delivery
- Intranasal nose‑to‑brain delivery
- Topical ocular penetration enhancement
News & Updates
The trial met its primary endpoints with all volunteers completing the dosing schedule with no adverse events.
Nanomerics' MET technology received patent protection in Canada for ocular use, joining patents in multiple territories.
Nanomerics received the prestigious award recognizing their innovative medicine technologies.
Uchegbu was awarded for services to the chemical sciences and diversity and inclusion.
The trial met its primary endpoints with all volunteers completing the dosing schedule with no adverse events.
Nanomerics' MET technology received patent protection in Canada for ocular use, joining patents in multiple territories.
Nanomerics received the prestigious award recognizing their innovative medicine technologies.
Uchegbu was awarded for services to the chemical sciences and diversity and inclusion.